Theravance Biopharma Inc Share Price Today: Live Updates & Key Insights

Theravance Biopharma Inc share price today is $14.33, up 2.28%. The stock opened at $13.935 against the previous close of $14.01, with an intraday high of $14.38 and low of $13.88.

Theravance Biopharma Inc Share Price Chart

Theravance Biopharma Inc

us-stock
To Invest in {{usstockname}}
us-stock

Theravance Biopharma Inc Share Price Performance

$14.33 0.0228(2.28%) TBPH at 23 Mar 2026 03:26 PM Biotechnology
Lowest Today 13.88
Highest Today 14.38
Today’s Open 13.935
Prev. Close 14.01
52 Week High 21.03
52 Week Low 7.90
Day’s Range: Low 13.88 High 14.38
52-Week Range: Low 7.90 High 21.03
1 day return -
1 Week return +3.15
1 month return -25.46
3 month return -23.6
6 month return +2.2
1 year return +52.7
3 year return +41.29
5 year return -29.69
10 year return -

Theravance Biopharma Inc Institutional Holdings

Madison Avenue Partners, LP 18.77

Weiss Asset Management LP 14.72

Newtyn Management LLC 8.49

BlackRock Inc 8.03

Irenic Capital Management LP 5.45

Vanguard Group Inc 4.67

D. E. Shaw & Co LP 2.49

Vanguard Total Stock Mkt Idx Inv 2.45

Oasis Management Co. Ltd 2.21

Acadian Asset Management LLC 2.15

State Street Corp 2.08

Arrowstreet Capital Limited Partnership 1.90

Geode Capital Management, LLC 1.85

iShares Russell 2000 ETF 1.83

Dimensional Fund Advisors, Inc. 1.70

Morgan Stanley - Brokerage Accounts 1.18

Two Sigma Investments LLC 1.06

Bank of America Corp 1.04

UBS Group AG 1.01

Qube Research & Technologies 0.93

JPMorgan Chase & Co 0.84

Marshall Wace Asset Management Ltd 0.83

Vanguard Institutional Extnd Mkt Idx Tr 0.80

Fidelity Small Cap Index 0.73

iShares Biotechnology ETF 0.70

State St Russell Sm/Mid Cp® Indx SL Cl I 0.63

Pacer US Small Cap Cash Cows 100 ETF 0.62

iShares Russell 2000 Growth ETF 0.50

Janus Henderson Small Cap Gr Alpha ETF 0.43

Nomura Healthcare Fund Class I 0.41

Janus Henderson Small/Md Cp Gr Alpha ETF 0.41

Fidelity Extended Market Index 0.39

Schwab US Small-Cap ETF™ 0.36

Vanguard Russell 2000 ETF 0.36

DFA US Small Cap I 0.36

BlackRock Global Equity Mkt Netrl Instl 0.35

Dimensional US Small Cap ETF 0.30

State Street® SPDR® S&P® PhrmctlsETF 0.29

BlackRock Advantage Small Cap Core Instl 0.29

DFA US Micro Cap I 0.29

Theravance Biopharma Inc Market Status

Strong Buy: 1

Buy: 1

Hold: 2

Sell: 0

Strong Sell: 0

Theravance Biopharma Inc Fundamentals

Market Cap 726.14 M

PB Ratio 3.1251

PE Ratio 25.1404

Enterprise Value 442.06 M

Total Assets 485.57 M

Volume 1486942

Theravance Biopharma Inc Company Financials

Annual Revenue FY23:54508000 54.5M, FY22:51346000 51.3M, FY21:55311000 55.3M, FY20:71857000 71.9M, FY19:73414000 73.4M

Annual Profit FY23:null 0.0M, FY22:51346000 51.3M, FY21:55311000 55.3M, FY20:71857000 71.9M, FY19:73414000 73.4M

Annual Net worth FY23:-57045000 -57.0M, FY22:-92824000 -92.8M, FY21:-199426000 -199.4M, FY20:-278017000 -278.0M, FY19:-236455000 -236.5M

Quarterly Revenue Q3/2025:19990000 20.0M, Q2/2025:26195000 26.2M, Q1/2025:15388000 15.4M, Q3/2024:16868000 16.9M, Q2/2024:14256000 14.3M

Quarterly Profit Q3/2025:11878000 11.9M, Q2/2025:15705000 15.7M, Q1/2025:3936000 3.9M, Q3/2024:16868000 16.9M, Q2/2024:4302000 4.3M

Quarterly Net worth Q3/2025:3615000 3.6M, Q2/2025:54835000 54.8M, Q1/2025:-13579000 -13.6M, Q3/2024:-12698000 -12.7M, Q2/2024:-16529000 -16.5M

About Theravance Biopharma Inc & investment objective

Company Information Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Organisation Biotechnology

Employees 97

Industry Biotechnology

CEO Mr. Rick E. Winningham M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Theravance Biopharma Inc FAQs

What is the share price of Theravance Biopharma Inc today?

The current share price of Theravance Biopharma Inc is $14.33.

Can I buy Theravance Biopharma Inc shares in India?

Yes, Indian investors can buy Theravance Biopharma Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Theravance Biopharma Inc shares in India?

You can easily invest in Theravance Biopharma Inc shares from India by:

Can I buy fractional shares of Theravance Biopharma Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Theravance Biopharma Inc?

Theravance Biopharma Inc has a market cap of $726.14 M.

In which sector does Theravance Biopharma Inc belong?

Theravance Biopharma Inc operates in the Biotechnology sector.

What documents are required to invest in Theravance Biopharma Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Theravance Biopharma Inc?

The PE ratio of Theravance Biopharma Inc is 25.14 and the PB ratio is 3.13.